Roni Tamari
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Roni Tamari as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06903702 · A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center · withdrawn · Acute Myeloid Leukemia · principal investigator
- Ph1NCT03531736 · T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaMemorial Sloan Kettering Cancer Center · active not recruiting · Myeloid Diseases · principal investigator
- N/ANCT02677064 · Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute LeukemiaMemorial Sloan Kettering Cancer Center · recruiting · Acute Leukemia, Newly Diagnosed, Relapsed · principal investigator
- Ph2NCT02350777 · T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell TransplantationMemorial Sloan Kettering Cancer Center · terminated · Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function · principal investigator
- Ph1NCT02193191 · Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell DiseaseMemorial Sloan Kettering Cancer Center · completed · Sickle Cell Disease · principal investigator
- Ph2NCT01995578 · Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapseMemorial Sloan Kettering Cancer Center · completed · Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML) · principal investigator
- Ph2NCT00629798 · Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)Memorial Sloan Kettering Cancer Center · completed · Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Incidental diagnosis of clonal hematopoiesis among healthy, unrelated, hematopoietic stem cell donors: A feasibility study of psychosocial, ethical, and clinical issuesR21CA287094 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2024 · $433,895 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:58 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.Biol Blood Marrow Transplant · 201451 citationsRCR 1.5